© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 3, 182-192,
February 6, 2002
© 2002 Oxford University Press
ARTICLE |
Lung Cancer Following Chemotherapy and Radiotherapy for Hodgkin's Disease
Affiliations of authors: L. B. Travis, R. E. Curtis, J. F. Fraumeni, Jr., E. Gilbert, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; M. Gospodarowicz, The Princess Margaret Hospital, University of Toronto, ON, Canada; E. A. Clarke, E. Holowaty, Cancer Care Ontario, Toronto; M. Andersson, H. Storm, Danish Cancer Society, Copenhagen, Denmark; B. Glimelius, I. Glimelius, Uppsala University, Stockholm, Sweden; T. Joensuu, Helsinki University Central Hospital, Finland; C. F. Lynch, The University of Iowa, Iowa City; F. E. van Leeuwen, The Netherlands Cancer Institute, Amsterdam; E. Pukkala, Finnish Cancer Registry, Helsinki; M. Stovall, The University of Texas M. D. Anderson Cancer Center, Houston; J. D. Boice, Jr., International Epidemiology Institute, Rockville, MD, and Vanderbilt University Departments of Medicine and Vanderbilt-Ingram Cancer Center, Nashville, TN.
Correspondence to: Lois B. Travis, M.D., National Institutes of Health, EPS #7086, Bethesda, MD 20892 (e-mail: travisl{at}epndce.nci.nih.gov).
Background: Lung cancer is a frequent cause of death in patients cured of Hodgkin's disease, but the contributions of chemotherapy, radiotherapy, and smoking are not well described. We quantified the risk of treatment-associated lung cancer, taking into account tobacco use. Methods: Within a population-based cohort of 19 046 Hodgkin's disease patients (diagnosed from 1965 through 1994), a case–control study of lung cancer was conducted. The cumulative amount of cytotoxic drugs, the radiation dose to the specific location in the lung where cancer developed, and tobacco use were compared for 222 patients who developed lung cancer and for 444 matched control patients. All statistical tests were two-sided. Results: Treatment with alkylating agents without radiotherapy was associated with increased lung cancer risk (relative risk [RR] = 4.2; 95% confidence interval [CI] = 2.1 to 8.8), as was radiation dose of 5 Gy or more without alkylating agents (RR = 5.9; 95% CI = 2.7 to 13.5). Risk increased with both increasing number of cycles of alkylating agents and increasing radiation dose (P for trend <.001). Among patients treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), risk increased with cumulative amounts of mechlorethamine and procarbazine (P<.001) when evaluated separately. Statistically significantly elevated risks of lung cancer were apparent within 1–4 years after treatment with alkylating agents, whereas excess risk after radiotherapy began 5 years after treatment and persisted for more than 20 years. Risk after treatment with alkylating agents and radiotherapy together was as expected if individual excess risks were summed. Tobacco use increased lung cancer risk more than 20-fold; risks from smoking appeared to multiply risks from treatment. Conclusions: Past treatments with alkylating agents and radiation therapy for Hodgkin's disease were associated with an increased risk of lung cancer in a dose-dependent and additive fashion. The precise risk estimates, however, should be interpreted cautiously, given the possible residual and enhancing effects of tobacco.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Green, M. Johnston, M. Trudeau, L. Schwartz, S. Poirier, G. Macartney, and D. Milliken Safe Handling of Parenteral Cytotoxics: Recommendations for Ontario J. Oncol. Pract, September 1, 2009; 5(5): 245 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lorenzo, M. Provencio, L. Lombardia, R. Diaz, J. Silva, M. Herrera, J. M. Garcia, C. Pena, V. Garcia, J. Romero, et al. Differential Genetic and Functional Markers of Second Neoplasias in Hodgkin's Disease Patients Clin. Cancer Res., August 1, 2009; 15(15): 4823 - 4828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Nathan, J. S. Ford, T. O. Henderson, M. M. Hudson, K. M. Emmons, J. N. Casillas, E. A. Lown, K. K. Ness, and K. C. Oeffinger Health Behaviors, Medical Care, and Interventions to Promote Healthy Living in the Childhood Cancer Survivor Study Cohort J. Clin. Oncol., May 10, 2009; 27(14): 2363 - 2373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Diller, E. J. Chow, J. G. Gurney, M. M. Hudson, N. S. Kadin-Lottick, T. I. Kawashima, W. M. Leisenring, L. R. Meacham, A. C. Mertens, D. A. Mulrooney, et al. Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published Findings J. Clin. Oncol., May 10, 2009; 27(14): 2339 - 2355. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. De Bruin, J. A. Burgers, P. Baas, M. B. van 't Veer, E. M. Noordijk, M. W. J. Louwman, J. M. Zijlstra, H. van den Berg, B. M. P. Aleman, and F. E. van Leeuwen Malignant mesothelioma after radiation treatment for Hodgkin lymphoma Blood, April 16, 2009; 113(16): 3679 - 3681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Ng, S. Li, D. Neuberg, R. Chi, D. C. Fisher, B. Silver, and P. M. Mauch A prospective study of pulmonary function in Hodgkin's lymphoma patients Ann. Onc., October 1, 2008; 19(10): 1754 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Frobisher, D. L. Winter, E. R. Lancashire, R. C. Reulen, A. J. Taylor, C. Eiser, M. C. G. Stevens, M. M. Hawkins, and on behalf of the British Childhood Cancer Survivor Extent of Smoking and Age at Initiation of Smoking Among Adult Survivors of Childhood Cancer in Britain J Natl Cancer Inst, August 6, 2008; 100(15): 1068 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Friedberg Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma Haematologica, March 1, 2008; 93(3): 336 - 338. [Full Text] [PDF]
|
|
|
|
 |
|
 L J Worrillow, A G Smith, K Scott, M Andersson, A J Ashcroft, G M Dores, B Glimelius, E Holowaty, G H Jackson, G L Jones, et al. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma J. Med. Genet., March 1, 2008; 45(3): 142 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis Multiple Primary Cancers: An Overview of the National Cancer Institute's Surveillance, Epidemiology, and End Results Program ASCO Educational Book, January 1, 2008; 2008(1): 413 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Ng Second Cancers after Hodgkin's Lymphoma: Long-term Risks ASCO Educational Book, January 1, 2008; 2008(1): 418 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sieniawski, T. Reineke, L. Nogova, A. Josting, B. Pfistner, V. Diehl, and A. Engert Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG) Blood, January 1, 2008; 111(1): 71 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Hodgson, E. S. Gilbert, G. M. Dores, S. J. Schonfeld, C. F. Lynch, H. Storm, P. Hall, F. Langmark, E. Pukkala, M. Andersson, et al. Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma J. Clin. Oncol., April 20, 2007; 25(12): 1489 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Boice Jr An Affair of the Heart J Natl Cancer Inst, February 7, 2007; 99(3): 186 - 187. [Full Text] [PDF]
|
|
|
|
|
|
B Klimm, H. Eich, H Haverkamp, A Lohri, P Koch, F Boissevain, G Trenn, P Worst, E Duhmke, R. Muller, et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group Ann. Onc., February 1, 2007; 18(2): 357 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ng and P. Mauch The impact of treatment on the risk of second malignancy after Hodgkin's disease Ann. Onc., December 1, 2006; 17(12): 1727 - 1729. [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis The Epidemiology of Second Primary Cancers Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2020 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Oeffinger, A. C. Mertens, C. A. Sklar, T. Kawashima, M. M. Hudson, A. T. Meadows, D. L. Friedman, N. Marina, W. Hobbie, N. S. Kadan-Lottick, et al. Chronic Health Conditions in Adult Survivors of Childhood Cancer. N. Engl. J. Med., October 12, 2006; 355(15): 1572 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Fenske, C. McMahon, D. Edwin, J. C. Jarvis, J. M. Cheverud, M. Minn, V. Mathews, M. A. Bogue, M. A. Province, H. L. McLeod, et al. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res., May 15, 2006; 66(10): 5029 - 5038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Das, A. K. Ng, C. C. Earle, P. M. Mauch, and K. M. Kuntz Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis Ann. Onc., May 1, 2006; 17(5): 785 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Y. Mudie, A. J. Swerdlow, C. D. Higgins, P. Smith, Z. Qiao, B. W. Hancock, P. J. Hoskin, and D. C. Linch Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study J. Clin. Oncol., April 1, 2006; 24(10): 1568 - 1574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yahalom Don't Throw Out the Baby With the Bathwater: On Optimizing Cure and Reducing Toxicity in Hodgkin's Lymphoma J. Clin. Oncol., February 1, 2006; 24(4): 544 - 548. [Full Text] [PDF]
|
|
|
|
|
|
B. F. Koontz, J. P. Kirkpatrick, R. W. Clough, R. G. Prosnitz, J. P. Gockerman, J. O. Moore, and L. R. Prosnitz Combined-Modality Therapy Versus Radiotherapy Alone for Treatment of Early-Stage Hodgkin's Disease: Cure Balanced Against Complications J. Clin. Oncol., February 1, 2006; 24(4): 605 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Travis, C. S. Rabkin, L. M. Brown, J. M. Allan, B. P. Alter, C. B. Ambrosone, C. B. Begg, N. Caporaso, S. Chanock, A. DeMichele, et al. Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations J Natl Cancer Inst, January 4, 2006; 98(1): 15 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Gospodarowicz and R. M. Meyer The Management of Patients with Limited-Stage Classical Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 253 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Klimm, T. Reineke, H. Haverkamp, K. Behringer, H. T. Eich, A. Josting, B. Pfistner, V. Diehl, and A. Engert Role of Hematotoxicity and Sex in Patients With Hodgkin's Lymphoma: An Analysis From the German Hodgkin Study Group J. Clin. Oncol., November 1, 2005; 23(31): 8003 - 8011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Forrest, D. E. Hogge, T. J. Nevill, S. H. Nantel, M. J. Barnett, J. D. Shepherd, H. J. Sutherland, C. L. Toze, C. A. Smith, J. C. Lavoie, et al. High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation J. Clin. Oncol., November 1, 2005; 23(31): 7994 - 8002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Behringer, K. Breuer, T. Reineke, M. May, L. Nogova, B. Klimm, T. Schmitz, L. Wildt, V. Diehl, and A. Engert Secondary Amenorrhea After Hodgkin's Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin's Lymphoma Study Group J. Clin. Oncol., October 20, 2005; 23(30): 7555 - 7564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Travis, S. D. Fossa, S. J. Schonfeld, M. L. McMaster, C. F. Lynch, H. Storm, P. Hall, E. Holowaty, A. Andersen, E. Pukkala, et al. Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors J Natl Cancer Inst, September 21, 2005; 97(18): 1354 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Re, R. K. Thomas, K. Behringer, and V. Diehl From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential Blood, June 15, 2005; 105(12): 4553 - 4560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Dranitsaris, M. Johnston, S. Poirier, T. Schueller, D. Milliken, E. Green, and B. Zanke Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature Journal of Oncology Pharmacy Practice, June 1, 2005; 11(2): 69 - 78. [Abstract] [PDF]
|
|
|
|
|
|
P. Das, A. K. Ng, M. A. Stevenson, and P. M. Mauch Clinical course of thoracic cancers in Hodgkin's disease survivors Ann. Onc., May 1, 2005; 16(5): 793 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S.J. Duchateau and M. P.M. Stokkel Second Primary Tumors Involving Non-small Cell Lung Cancer: Prevalence and Its Influence on Survival Chest, April 1, 2005; 127(4): 1152 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rueda Dominguez, A. Marquez, J. Guma, M. Llanos, J. Herrero, M. A. de las Nieves, J. Miramon, and E. Alba Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study Ann. Onc., December 1, 2004; 15(12): 1798 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Behringer, A. Josting, P. Schiller, H. T. Eich, H. Bredenfeld, V. Diehl, and A. Engert Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group Ann. Onc., July 1, 2004; 15(7): 1079 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Oeffinger and M. M. Hudson Long-term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk-based Health Care for Survivors CA Cancer J Clin, July 1, 2004; 54(4): 208 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Andre, N. Mounier, X. Leleu, A. Sonet, P. Brice, M. Henry-Amar, H. Tilly, B. Coiffier, A. Bosly, P. Morel, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients Blood, February 15, 2004; 103(4): 1222 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M.P. Aleman, A. W. van den Belt-Dusebout, W. J. Klokman, M. B. van't Veer, H. Bartelink, and F. E. van Leeuwen Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin's Disease J. Clin. Oncol., September 15, 2003; 21(18): 3431 - 3439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis, D. A. Hill, G. M. Dores, M. Gospodarowicz, F. E. van Leeuwen, E. Holowaty, B. Glimelius, M. Andersson, T. Wiklund, C. F. Lynch, et al. Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease JAMA, July 23, 2003; 290(4): 465 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. E. van Leeuwen, W. J. Klokman, M. Stovall, E. C. Dahler, M. B. van't Veer, E. M. Noordijk, M. A. Crommelin, B. M. P. Aleman, A. Broeks, M. Gospodarowicz, et al. Roles of Radiation Dose, Chemotherapy, and Hormonal Factors in Breast Cancer Following Hodgkin's Disease J Natl Cancer Inst, July 2, 2003; 95(13): 971 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kattlove and R. J. Winn Ongoing Care of Patients After Primary Treatment for Their Cancer CA Cancer J Clin, May 1, 2003; 53(3): 172 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Dores, C. Metayer, R. E. Curtis, C. F. Lynch, E. A. Clarke, B. Glimelius, H. Storm, E. Pukkala, F. E. van Leeuwen, E. J. Holowaty, et al. Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin's Disease: A Population-Based Evaluation Over 25 Years J. Clin. Oncol., August 15, 2002; 20(16): 3484 - 3494. [Abstract] [Full Text] [PDF]
|
|